Finklea James D, Hollaway Rita, Lowe Karen, Lee Francesca, Le Jade, Jain Raksha
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Diagn Microbiol Infect Dis. 2018 Sep;92(1):75-77. doi: 10.1016/j.diagmicrobio.2018.05.002. Epub 2018 May 12.
Ceftolozane/tazobactam is a combination intravenous antibiotic with potentially important activity against drug-resistant Gram-negative organisms. Ceftolozane/tazobactam's in vitro activity was evaluated in 30 samples collected from 23 adult cystic fibrosis patients with extended and pan-resistant Pseudomonas aeruginosa in 2015. Testing results demonstrated that 30% of the isolates were susceptible,13% were intermediate, and 57% were resistant. This suggests that ceftolozane/tazobactam may be a useful antibiotic in carefully selected, multidrug-resistant Pseudomonas isolates.
头孢洛扎/他唑巴坦是一种静脉注射用抗生素组合，对耐药革兰氏阴性菌具有潜在的重要活性。2015年，从23例患有广泛耐药和全耐药铜绿假单胞菌的成年囊性纤维化患者中收集了30份样本，对头孢洛扎/他唑巴坦的体外活性进行了评估。检测结果表明，30%的分离株敏感，13%为中介，57%耐药。这表明，在经过精心挑选的多重耐药铜绿假单胞菌分离株中，头孢洛扎/他唑巴坦可能是一种有用的抗生素。
